The total number of shares and votes in Oasmia Pharmaceutical AB (publ) amounts to 88,072,330 as of July 31, 2014. The increase in the number of shares is attributable to aprivate placement that was carried out in July 2014, which comprised 2,500,000 shares.The share issue was registered in its entirety with the Swedish Companies Registration Office on July 9, 2014.

A list of the company principal shareholders will be available at

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human andveterinary oncology. The company’s product development aims to create and manufacturenovel nanoparticle formulations and drug-delivery systems based on well-establishedcytostatics, which in comparison with current alternatives show improved properties,reduced side effects, and expanded applications. The company’s product development isbased on its proprietary in-house research and company patents. Oasmia is listed onNASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).